| Overall participants | Participants with diabetes | Participants with pre-diabetes | |||
---|---|---|---|---|---|---|
 | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P |
Overall survival | 662 deaths | Â | 347 deaths | Â | 315 deaths | Â |
AgeAccelGrim2 T1 | Reference | Reference | Reference | Reference | Reference | Reference |
AgeAccelGrim2 T2 | 1.113 (0.906, 1.367) | 0.310 | 1.022 (0.775, 1.349) | 0.875 | 1.171 (0.863, 1.590) | 0.310 |
AgeAccelGrim2 T3 | 1.619 (1.298, 2.019) |  < 0.001 | 1.515 (1.128, 2.036) | 0.006 | 1.568 (1.119, 2.199) | 0.009 |
Cardiovascular Death | 187 deaths | Â | 103 deaths | Â | 84 deaths | Â |
AgeAccelGrim2 T1 | Reference | Reference | Reference | Reference | Reference | Reference |
AgeAccelGrim2 T2 | 1.039 (0.700, 1.542) | 0.849 | 1.001 (0.594, 1.687) | 0.997 | 1.153 (0.616, 2.159) | 0.791 |
AgeAccelGrim2 T3 | 1.802 (1.194, 2.720) | 0.005 | 1.815 (1.065, 3.094) | 0.028 | 1.995 (1.026, 3.878) | 0.042 |
Non-Cardiovascular Death | 475 deaths | Â | 244 deaths | Â | 231 deaths | Â |
AgeAccelGrim2 T1 | Reference | Reference | Reference | Reference | Reference | Reference |
AgeAccelGrim2 T2 | 1.139 (0.895, 1.449) | 0.290 | 1.029 (0.741, 1.428) | 0.865 | 1.176 (0.829, 1.668) | 0.365 |
AgeAccelGrim2 T2 | 1.548 (1.192, 2.012) | 0.001 | 1.396 (0.978, 1.993) | 0.066 | 1.450 (0.978, 2.149) | 0.065 |